Concord Biotech Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹312 Cr +26.3% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
CB

Concord Biotech Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Concord Biotech Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹247Cr
−20.3% YoY
+21.1% QoQ
Net profit
₹63Cr
−36.4% YoY
+46.5% QoQ
Margin
37%
−7 pp YoY
+7 pp QoQ
Price₹1,571
Market cap₹14.5K Cr
P/E51.0

The short version

Expected stronger revenue performance in H2 FY26 compared to H2 FY25, with growth anticipated to recover from timing-related setbacks. Concord Biotech anticipates a 25% CAGR driven by: - Capacity ramp-up in injectable units. - Growth in CDMO (Contract Development and Manufacturing Organization) business. - H2 FY26 expected to show better growth compared to H2 FY25, though exact magnitude is uncertain due to external factors. - Temporary issues (EU approval delays, Middle East contract deferment, U.S.

From Concord Biotech Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Expected stronger revenue performance in H2 FY26 compared to H2 FY25, with growth anticipated to recover from timing-related setbacks.
  • Long-term target to achieve a 25% CAGR supported by new facilities, expanded product mix, and ramping up of injectable and CDMO businesses.
  • Injectable facility commercialization progressing; revenues to pick up from India market initially, followed by emerging markets after 12-18 months.
  • Recovery of deferred revenues from EU and Middle East contracts expected in coming quarters, mitigating recent declines.
  • Positive traction in second-source opportunities and ongoing CDMO projects expected to contribute to future growth.

2 more points from Concord Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Concord Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • It highlights the commissioning of a new injectable facility in March, indicating recent capital investment.
  • The injectable facility is expected to ramp up commercial activity, targeting the Indian market initially, and expanding to emerging markets after 12-18 months.
  • Development work in CAR-T cell therapy is underway, focusing on development for 12-15 months, which suggests ongoing R&D investment.

2 more points from Concord Biotech Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Concord Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Currently, Concord Biotech has one commercial CDMO project underway with sales having started and progressing well.
  • Additional CDMO projects have been commercialized but are relatively small and in initial stages, serving as inroads to build larger relationships with global MNC clients.
  • Discussions are ongoing with two potential innovator companies for CDMO opportunities; one was temporarily on hold due to external tariff issues but has now resumed with renewed engagement.
  • Visibility on full-year CDMO revenues and orderbook clarity is expected next year as products launch and ramp-up occurs.

2 more points from Concord Biotech Ltd's call on order book

Create a free account to keep reading this call

Concord Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Concord Biotech Ltd Q2 FY26 results — key figures

Concord Biotech Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue247310-20.3%204+21.1%
Operating profit (EBITDA)91137-33.6%61+49.2%
Operating margin37%44%-7 pp30%+7 pp
Profit before tax86133-35.3%57+50.9%
Net profit (PAT)6399-36.4%43+46.5%
EPS (₹)3.014.72-36.2%2.03+48.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹312 Cr, net profit ₹76 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Concord Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Concord Biotech Ltd Q2 FY26 results?

Expected stronger revenue performance in H2 FY26 compared to H2 FY25, with growth anticipated to recover from timing-related setbacks. Concord Biotech anticipates a 25% CAGR driven by: - Capacity ramp-up in injectable units. - Growth in CDMO (Contract Development and Manufacturing Organization) business. - H2 FY26 expected to show better growth compared to H2 FY25, though exact magnitude is uncertain due to external factors. - Temporary issues (EU approval delays, Middle East contract deferment, U.S.

What is Concord Biotech Ltd share price analysis?

Concord Biotech Ltd currently shows a neutral. The stock trades at a P/E of 51.0 with a market cap of ₹14,489 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Concord Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.